Gonca OZAN, Hakan UFAT, Penbe Sema TEMİZER OZAN

Diyabet Oluşturulan Ratlarda Serum Apelin ve Chemerin Düzeyleri

Diyabet, insülin sekresyonunun azlığı sonucu metabolik bozukluklara sebep olan yaşam süresi ve kalitesini olumsuz etkileyen bir grup metabolizma hastalığıdır. Çalışmada streptozotosin ile diyabet oluşturulan ratlarda glukoz metabolizması ile ilişkisi olduğu düşünülen apelin ve chemerin'in 7, 14 ve21.günlerdeki düzeylerinin saptanması amaçlandı ve apelin, chemerin düzeylerinin diyabet ile ilişkisini saptamak amacıyla da adipokinlerin insülin direnci ve beta-hücrefonksiyonları arasında her hangi bir ilginin olup olmadığı araştırıldı.Çalışmada 5 haftalık Sprague Dawley cinsi 37 erkek rat kullanıldı. Denekler rastgele 2 gruba ayrıldı. I.Kontrol (n=7) grubu olup ratlara standart beslenme uygulandı, II.Diyabet grubu (n=30) olup 65mg/kg intraperitoneal tek doz streptozotosin uygulanmasını takiben 3.günün sonunda kuyruk veninden alınan kanglukoz düzeylerininin 200 mg/dLüzeri olmasının tespiti ile ratlar diyabetik kabul edildi. Diyabetik grupta 3 gruba ayrıldı. 1.Diyabetik grup 7.günde, 2.Diyabetik grup 14.gün ve 3.Diyabetik grup da 21.gün sonunda anestezi altında dekapite edilip, serumları alındı.Kontrol grubuna göre diyabet oluşturulan gruplarda serum apelin, chemerin, insülin, C-peptid, HbA1-C, LDL ve ürik asit parametrelerinde anlamlı olmayan değişiklikler saptandı.Kontrol grubu ile diyabet ve diyabet gruplarının da kendi aralarında anlamlı (P>0.05) bir fark bulunmamasına rağmen diyabet oluşturulan gruplar arasında rakamsal olarak serum apelin, chemerin, insülin, C-peptid, HbA1-C, LDL ve ürik asit düzeylerinin günlere bağlı olarak arttığı tespit edildi ve serum glukoz, glukoz1, HDL, trigliserit, kolesterol, HbA1C düzeylerinde ise anlamlı (P0.05).

Serum Apelin and Chemerin Levels in Streptozotocine Induced Diabetic Rats

Diabetes, is a group ofmetabolic diseases, causing metabolic disorders decreasing the lifespan and quality of life because of insulin deficiency.The purpose of the study was to check apelin and chemerin levels on the 7th, 14th, and 21st days,respectively in rats made diabeticwith Streptozotocin. Accordingly,it was also investigatedif there was any relationship between insulin resistance of Adipokins and Beta cell functions to exhibit relation inbetween apelin and chemerin levels and diabetes.Five weeks old, 37 male Spraugue Dawley rats were used in study. Rats were divided into 2 groups. 1.Control Group (n=7) fed by standard method. 2.Diabetic Group (n= 30); rats were initially given 65mg/kg intraperitoneal single dose Streptozotocin and after 3 days,blood glucose levels measured from tail veins showed over 200 mg/dLand rats were confirmed diabetics(DM). DM group were divided into 3 sub-groups. First sub-diabetic group ended on 7thday(DM7), second sub-diabetic group ended on 14thday(DM14), and third sub-diabeticgroup ended on 21stday (DM 21) and decapitated and blood samples were taken.In all diabetics groups, compared to control group, no significant differences were detected in apelin, chemerin, insulin, C-peptid, HbA1-C, LDL, uric acid parameters.Despite there wasno significant changebetween control and diabetics, there were some numerical increase between sub-diabetics groups serum levels apelin, chemerin insulin, C-Peptid, HbA1-C, LDL and uric acid based on day and serum glucose, glucose1, HDL, triglyceride, cholesterol, and HbA1C levels had significant changes(P0.05)by time

PDF

___

1.Yenigün M. Her Yönüyle Diabetes Mellitus. 2. Baskı,İstanbul: İstanbul Nobel Tıp Kitabevi,2004.
2.King H, Rewers M. WHO Ad Hoc diabetes reporting group: Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 1993; 16: 157-77.
3.King H, Aubert RF, Herman WH. Global burden of diabetes, 1995-2025: Prevalence, numerical estimates and projections. Diabetes Care 1998; 21: 1414-1431
4.SchleinitzD.Genetic determination of serum levels of diabetes-associated adipokines.Rev Diabet Stud 2015; 12:e2015014.
5.Garvey WT, Birnbaum MJ. Cellular insulin action and insulin resistance. BaillieresClin Endocrinol Metab1993; 7: 785-873.
6.Kadoglou NP, Fotiadis G, Kapelouzou A, et al. The differential anti-inflammatory effects of exercise modalities and their association with early carotid atherosclerosis progression in patients with type 2 diabetes. Diabet Med2013; 30:e41-50
7.Tatemoto K, Takayama K, Zou MX, et al.The novel peptide apelin lowers blood pressure via a nitric oxide-dependent mechanism. Regul Pept 2001; 99: 87-92.
8.O'Dowd BF, Heiber M, Chan A, et al. A human gene that shows identity with the gene encoding the angiotensin receptor is located on chromosome 11. Gene 1993; 136: 355-360.
9.Tatemoto K, Hosoya M, Habata Y, et al. Isolation and characterization of a novel endogenous peptide ligand for the human APJ receptor. Biochem Biophys Res Commun 1998; 251: 471-476.
10.Lee DK, Cheng R, Nguyen T, et al. Characterization of apelin, the ligand for the APJ receptor. J Nerochem 2000; 74: 34-41.
11.Beltowski J.Apelin and visfatin: Unique "beneficial" adipokines upregulated in obesity? Med Sci Monit 2006; 12: 112-119.
12.Baranova A, Randhawa M,Jarrar M,Younossi ZM. Adipokines and melanocortins in the hepatic manifestation of metabolic syndrome: Nonalcoholic fatty liver disease.Expert Rev Mol Diagn 2007; 7: 195-205.
13.Liorens-Cortes C, Beaudet A. Apelin, a neuropepide that counter actsvasopressin secretion. Med Sci2005; 21: 741-746.
14.Kralisch S, Klein J, Bluher M, et al. Therapeutic perspectives of adipocytokines. Expert Opin Pharmacother 2005; 6: 863-872.
15.Medhurst AD, Jennings CA, Robbins MJ, et al. Pharmacological and immunohistochemical characterization of the APJ receptor and it endogenous ligand apelin. J Nerochem 2003; 308: 480-485.
16.Bozaoğlu K,Bolton K, McMillan J, et al. Chemerin is a novel adipokine associated with obesity and metabolic syndrome.Endocrinology2007; 148: 4687-4694
17.Stejskal D, Karpisek M, Hanulova Z, Svestak M. Chemerin is an independent marker of the metabolic syndrome in a caucasian population -a pilot study. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub2008; 152:217-221.
18.Zhang B, Zhang Y.Mann-Whitney U test and Kruskal-Wallis test should be used for comparisons of differences in medians, not means: Comment on the article by van der Helm-van Mil et al.Arthritis Rheum2009;60:1565.
19.Mitrakou A, Kelly D, Mokan M, et al. Role of reduced supression of glucose production and diminished early insulin release in impaired glucose tolerance. NEngl J Med 1992; 326: 22-29.
20.Tai ES, Goh ES, Lee JJM,et al. Lowering the criterion for impaired fasting glucose impact on disease prevalence and associated risk of diabetes and ischemic heart disease. Diabetes Care 2004; 27: 1728-1734.
21.Oto A, Kepez A. İnsülin Direncinin Patofizyolojik Temelleri ve Kardiyovasküler Hastalıklarla İlişkisi. Türk Kardiyoloji Seminerleri 2005; 5: 192-208.
22.Trayhurn P, Bing C, Wood IS. Adipose tissue and adipokines-energy regulation from the human perspective. J Nutr2006; 136: 1935-1939.
23.Gimble JM. Adipose tissue-derived therapeutics.Expert Opin Biol Ther 2003; 3: 705-713.
24.Li L, Yang G, Li Q, et al.Changes and relations of circulating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. ExpClin Endocrinol Diabetes 2006; 114:544-548.
25.Şenol MG, Terekeci HM, İpçioğlu O, et al. Plasma apelin levels in diabetic patients with and without neuropathy. CentEur J Med 2009; 4: 241-244.
26-Erdem G, Dogru T, Tasci I, Sonmez A, Tapan S. Low plasma apelin levels in newly diagnosed type 2 diabetes mellitus. Exp Clin Endocrinol Diabetes 2008; 116:289-292.
27-Tasci I, Erdem G, Ozgur G, et al. LDL-cholesterol lowering increases plasma apelin in isolated hypercholesterolemia. Atherosclerosis 2009; 204: 222-228.
28-Lago F, Dieguez C, Reino JG, Gualillo O. The emerging role of adipokines as mediators of inflammation and immune responses. Science Direct2007; 18: 313-325.
29-Takahashi M, Takahashi Y, Takahashi K, et al. Chemerin enhances insulin signaling and potentiates insulin-stimulated glucose uptake in 3T3-L1 adipocytes FEBS Letters 2008;582; 573-578.
30-Parolini S, Santoro A,MarcenaroE,et al. The role of chemerin in the colocalization of NK and dendritic cell subsets into inflamed tissues. Blood J 2007; 109: 3625-3632.